1292954-98-3

Basic information

• Product Name: C₂₅H₃₆N₄O₅
• CAS NO: 1292954-98-3
• Molecular Weight: 472.585
• Mol File: 1292954-98-3.mol

Chemical Properties

• CAS DataBase Reference: C₂₅H₃₆N₄O₅(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₅H₃₆N₄O₅(1292954-98-3)
• EPA Substance Registry System: C₂₅H₃₆N₄O₅(1292954-98-3)

Safety Data

• Hazardous Substances Data: 1292954-98-3(Hazardous Substances Data)

Upstream product

• 1292954-97-2 C₃₄H₅₆N₄O₅Si 
• 1292954-96-1 tert-butyl methyl(6-(2-(6-(2-(triisopropylsilyloxy)ethyl)pyridin-2-ylamino)-ethyl)pyridin-2-yl)carbamate 
• 1292954-95-0 2-bromo-6-(2-(triisopropylsilyloxy)ethyl)pyridine 
• 1292954-90-5 tert-butyl 6-(2-aminoethyl)pyridin-2-yl(methyl)carbamate 
• 1292954-89-2 tert-butyl 6-(2-azidoethyl)pyridin-2-yl(methyl)carbamate 
• 1292954-88-1 C₁₄H₂₂N₂O₅S 
• 955370-07-7 2-(6-bromopyridin-2-yl)ethan-1-ol 
• 1824-81-3 2-Amino-6-methylpyridine 
• 243640-97-3 tert-butyl 6-(2-hydroxyethyl)pyridin-2-yl(methyl)carbamate 
• 205676-84-2 (tert-butoxy)-N-methyl-N-[6-methyl-(2-pyridyl)]carboxamide 
• 90101-22-7 2-(tert-butoxycarbonylamino)-6-picoline 
• 5315-25-3 2-bromo-6-methylpyridine 
• 24424-99-5 di-tert-butyl dicarbonate 

Relevant articles and documents

Synthesis and structure–activity relationship of 2,6-disubstituted pyridine derivatives as inhibitors of β-amyloid-42 aggregation

It is assumed that amyloid-β aggregation is a crucial event in the pathogenesis of Alzheimer's disease. Novel 2,6-disubstituted pyridine derivatives were designed to interact with the β-sheet conformation of Aβ via donor–acceptor–donor hydrogen bond forma

2,6-Diaminopyridine Compounds Suitable For Treating Diseases Associated With Amyloid Or Amyloid-Like Proteins Or For Treating Or Preventing Ocular Diseases Or Conditions Associated With A Pathological Abnormality/Change In The Tissue Of The Visual System

The present invention relates to 2,6-diaminopyridine compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system.

2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases

The present invention relates to 2,6-diaminopyridine compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein and of diseases or conditions associated with amyloid-like proteins. The compoun

2,6-DIAMINOPYRIDINE COMPOUNDS SUITABLE FOR TREATING DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS OR FOR TREATING OR PREVENTING OCULAR DISEASES OR CONDITIONS ASSOCIATED WITH A PATHOLOGICAL ABNORMALITY/CHANGE IN THE TISSUE OF THE VISUAL SYSTEM

The present invention relates to 2.6-diaminopyridine compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein and of diseases or conditions associated with amyloid-like proteins. The compoun